Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Jennings, Barbara A ^a   Loke, Yoon K ^a   Skinner, Jane ^a   Keane, Melanie ^b   Chu, Gavin S ^b   Turner, Richard ^b   Epurescu, Daniel ^b   Barrett, Ann ^b   Willis, Gavin ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; 5-FLUOROPYRIMIDINE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DPYD GENE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; OBSERVATIONAL STUDY; ONCOGENE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; TREATMENT DURATION; TYMP GENE; ADULT; AGED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHARMACOGENETICS; PYRIMIDINES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84885972572     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078053     Document Type: Article

References (50)

1. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, et al. (2011) PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21: 237-242. PubMed: 20601926.
2. Longley DB, Harkin DP, Johnston PG, (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338. doi:10.1038/nrc1074. PubMed: 12724731.
3. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106. PubMed: 11689577.
4. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575. doi:10.1093/annonc/mdf089. PubMed: 12056707.
5. Zhang C, Wang J, Gu H, Zhu D, Li Y, et al. (2012) Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncol Lett 3: 831-838. PubMed: 22741002.
6. Zaniboni A, (1997) Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15: 2432-2441. PubMed: 9196159.
7. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D, (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752-755. doi:10.1136/bmj.306.6880.752. PubMed: 7683942.
8. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351. doi:10.1056/NEJMoa032709. PubMed: 15175436.
9. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, et al. (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27: 5519-5528. doi:10.1200/JCO.2008.21.6283. PubMed: 19858398.
10. Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B, (2009) A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer 8: 43-48. doi:10.3816/CCC.2009.n.007. PubMed: 19203896.
11. Fernández-Contreras ME, Sánchez-Hernández JJ, Guijarro M, Gisbert JP, Rivas N, et al. (2010) Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep 23: 1393-1400. PubMed: 20372856.
12. Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, et al. (2009) Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 100: 1549-1557. doi:10.1038/sj.bjc.6605052. PubMed: 19384296.
13. Hitre E, Budai B, Adleff V, Czeglédi F, Horváth Z, et al. (2005) Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 15: 723-730. doi:10.1097/01.fpc.0000175598.42141.59. PubMed: 16141798.
14. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, et al. (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254. doi:10.1200/JCO.2006.08.1844. PubMed: 17401013.
15. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, et al. (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8: 278-288. doi:10.1038/sj.tpj.6500463. PubMed: 17549067.
16. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, et al. (2011) Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11: 61-71. doi:10.1038/tpj.2010.10. PubMed: 20177420.
17. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, et al. (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17: 3455-3468. doi:10.1158/1078-0432.CCR-10-2209. PubMed: 21498394.
18. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, et al. (2010) The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 65: 403-406. doi:10.1007/s00280-009-1147-x. PubMed: 19795123.
19. Vignoli M, Nobili S, Napoli C, Putignano AL, Morganti M, et al. (2011) Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res 64: 242-248. doi:10.1016/j.phrs.2011.04.006. PubMed: 21536130.
20. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, et al. (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249: 271-282. doi:10.1016/j.canlet.2006.09.006. PubMed: 17064846.
21. Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, et al. (2013) Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J 13: 209-217. doi:10.1038/tpj.2012.2. PubMed: 22310351.
22. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, et al. (2012) Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics 22: 290-304. doi:10.1097/FPC.0b013e328351875d. PubMed: 22388795.
23. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, et al. (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26: 2131-2138. doi:10.1200/JCO.2006.10.4182. PubMed: 18299612.
24. Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W, Kładny J, Gziut K, et al. (2008) 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep PR 60: 238-242. PubMed: 18443386.
25. Goodwin RA, Asmis TR, (2009) Overview of systemic therapy for colorectal cancer. Clin Colon Rect Surg 22: 251-256. doi:10.1055/s-0029-1242465. PubMed: 21037816.
26. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113. doi:10.1038/ng0595-111. PubMed: 7647779.
27. Gellekink H, Blom HJ, van der Linden IJ, den Heijer M, (2007) Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels. Eur J Hum Genet 15: 103-109. doi:10.1038/sj.ejhg.5201713. PubMed: 16969375.
28. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K, (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191-197. doi:10.1247/csf.20.191. PubMed: 7586009.
29. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, et al. (1987) Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259-1270. doi:10.1093/nar/15.3.1259. PubMed: 3029702.
30. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, et al. (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096-4101. PubMed: 11751507.
31. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, et al. (2003) A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904. PubMed: 12782596.
32. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, et al. (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319-327. doi:10.1097/00008571-200405000-00007. PubMed: 15115918.
33. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R, (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172. doi:10.1006/mgme.1998.2714. PubMed: 9719624.
34. Johnson WG, Scholl TO, Spychala JR, Buyske S, Stenroos ES, et al. (2005) Common dihydrofolate reductase 19-base pair deletion allele: a novel risk factor for preterm delivery. Am J Clin Nutr 81: 664-668. PubMed: 15755837.
35. Peter L, Rady SKT, Hudnall S David, Vargas, Trini, Kellner Leonard H, Nitowsky Harold, Matalon Reuben K (1999) Methylenetetrahydrofolate reductase (MTHFR): The incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 86: 380-384. doi:10.1002/(SICI)1096-8628(19991008)86:4. PubMed: 10494095.
36. Sharp L, Little J, (2004) Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159: 423-443. doi:10.1093/aje/kwh066. PubMed: 14977639.
37. Willis G, Scott DG, Jennings BA, Smith K, Bukhari M, et al. (2002) HFE mutations in an inflammatory arthritis population. Rheumatology (Oxf) 41: 176-179. doi:10.1093/rheumatology/41.2.176.
38. Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, et al. (2011) 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics 12: 251-265. doi:10.2217/pgs.10.167. PubMed: 21332317.
39. Caronia D, Martin M, Sastre J, de la Torre J, Garcia-Saenz JA, et al. (2011) A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res Off J Am Assoc Cancer Res 17: 2006-2013. doi:10.1158/1078-0432.CCR-10-1741.
40. Fariña-Sarasqueta A, van Lijnschoten G, Rutten HJ, van den Brule AJ, (2010) Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. Cancer Chemother Pharmacol 66: 1167-1171. doi:10.1007/s00280-010-1403-0. PubMed: 20665215.
41. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R, (2006) Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res Off J Am Assoc Cancer Res 12: 3928-3934. doi:10.1158/1078-0432.CCR-05-2665. PubMed: 16818689.
42. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, et al. (2003) A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904. PubMed: 12782596.
43. Kawakami K, Watanabe G, (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004-6007. PubMed: 14522928.
44. Yawata A, Kim SR, Miyajima A, Kubo T, Ishida S, et al. (2005) Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother Pharmacol 56: 465-472. doi:10.1007/s00280-005-1018-z. PubMed: 15918040.
45. de Bock CE, Garg MB, Scott N, Sakoff JA, Scorgie FE, et al. (2011) Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo. Pharmacogenomics J 11: 307-314. doi:10.1038/tpj.2010.43. PubMed: 20531375.
46. Afzal S, Gusella M, Jensen SA, Vainer B, Vogel U, et al. (2011) The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics 12: 1257-1267. doi:10.2217/pgs.11.83. PubMed: 21919605.
47. Pullmann R Jr., Abdelmohsen K, Lal A, Martindale JL, Ladner RD, et al. (2006) Differential stability of thymidylate synthase 3'-untranslated region polymorphic variants regulated by AUF1. J Biol Chem 281: 23456-23463. doi:10.1074/jbc.M600282200. PubMed: 16787927.
48. Perneger TV, (1998) What's wrong with Bonferroni adjustments. BMJ 316: 1236-1238. doi:10.1136/bmj.316.7139.1236. PubMed: 9553006.
49. Taflin H, Wettergren Y, Odin E, Carlsson G, Derwinger K, (2011) Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. Anticancer Res 31: 3057-3062. PubMed: 21868559.
50. Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, et al. (2011) Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res 17: 3822-3829. doi:10.1158/1078-0432.CCR-11-0304. PubMed: 21471424.